| __timestamp | Corcept Therapeutics Incorporated | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 34916000 | 10811000 |
| Thursday, January 1, 2015 | 36949000 | 33001000 |
| Friday, January 1, 2016 | 45240000 | 64936000 |
| Sunday, January 1, 2017 | 62416000 | 99909000 |
| Monday, January 1, 2018 | 81289000 | 127724000 |
| Tuesday, January 1, 2019 | 100359000 | 161524000 |
| Wednesday, January 1, 2020 | 105326000 | 182933000 |
| Friday, January 1, 2021 | 122356000 | 219982000 |
| Saturday, January 1, 2022 | 152848000 | 278139000 |
| Sunday, January 1, 2023 | 184259000 | 309799000 |
Infusing magic into the data realm
In the dynamic world of biotechnology, understanding financial trends is crucial for investors and stakeholders. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent biotech companies: Corcept Therapeutics Incorporated and Ultragenyx Pharmaceutical Inc., from 2014 to 2023.
Corcept Therapeutics has seen a steady increase in SG&A expenses, growing by approximately 428% over the decade. In 2014, their expenses were around 35 million, which surged to nearly 184 million by 2023. This growth reflects their expanding operations and market presence.
On the other hand, Ultragenyx Pharmaceutical Inc. experienced an even more dramatic rise, with SG&A expenses increasing by over 2800% from 2014 to 2023. Starting at just over 10 million in 2014, their expenses reached a staggering 310 million in 2023, highlighting their aggressive expansion and investment in research and development.
These trends underscore the competitive nature of the biotech industry, where strategic financial management is key to sustaining growth and innovation.
Cost Management Insights: SG&A Expenses for Vertex Pharmaceuticals Incorporated and Ultragenyx Pharmaceutical Inc.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Corcept Therapeutics Incorporated Trends and Insights
Alnylam Pharmaceuticals, Inc. vs Corcept Therapeutics Incorporated: SG&A Expense Trends
Comparing SG&A Expenses: Teva Pharmaceutical Industries Limited vs Ultragenyx Pharmaceutical Inc. Trends and Insights
Insmed Incorporated and Corcept Therapeutics Incorporated: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Corcept Therapeutics Incorporated and Rhythm Pharmaceuticals, Inc.
Corcept Therapeutics Incorporated vs Bausch Health Companies Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Corcept Therapeutics Incorporated and Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: Corcept Therapeutics Incorporated vs BioCryst Pharmaceuticals, Inc. Trends and Insights
Comparing SG&A Expenses: Ultragenyx Pharmaceutical Inc. vs Perrigo Company plc Trends and Insights
Selling, General, and Administrative Costs: Ultragenyx Pharmaceutical Inc. vs Taro Pharmaceutical Industries Ltd.
Breaking Down SG&A Expenses: Ultragenyx Pharmaceutical Inc. vs MiMedx Group, Inc.